A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Keywords:
Niraparib
Platinum based chemotherapy
BRCA status
Atezolizumab
Death-ligand 1 (PD-L1)
ADP-ribose
Anti-PD-L1/programmed cell death protein
Atezolizumab and NIraparib Treatment Association (ANITA)
Editorial note:
© IGCS and ESGO 2021. No commercial re-use.
Citation:
Sánchez-Lorenzo, M. L. (María Luisa); González-Martín, A. (Antonio); Colombo, N. (Nicoletta); et al. "A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial". International Journal of Gynecological Cancer. 31, 2021, 617 - 622
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.